Upcoming: June 3-5, 2027, ILROG-NEXT 2027, Boston, MA
Ongoing Research

Completed Research

Recently completed ILROG trials and collaborative studies, with links to the published results.

Clinical Trials

30 Gy reduced to 20 Gy

Diffuse large B-cell lymphoma

Accrual complete

Study of Dose-Reduced Consolidation Radiation Therapy in Patients with Diffuse Large B-cell Lymphoma

This phase II study will evaluate whether a reduction in the dose of consolidation RT in patients who achieve a negative post-chemotherapy PET-CT scan following 3 to 6 cycles of chemoimmunotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity. The hypothesis is that after more effective systemic therapy (employing rituximab), and confirmation of optimal response to chemotherapy (negative post-chemotherapy PET-CT), the RT dose can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control.

Principal Investigators
Dr Chris Kelsey (Duke)
Participating Institutions
Duke, MD Anderson Cancer Center, Yonsei Cancer Center, Juntendo University, SingHealth, University of Rochester, Mayo Clinic, Dana-Farber/Brigham and Women's

241 patients enrolled; accrual completed in 2023. Long-term results of the original Duke phase 2 study were published in 2025.

Download the protocol (PDF)NCT03681535 on ClinicalTrials.govLong-term update of the Duke phase 2 study (IJROBP 2025)

4 Gy in 2 fractions

Multiple myeloma, painful bone lesions

Results presented

Multi-Institutional Study of Low-Dose (2Gy x 2) Palliative Radiotherapy in the Treatment of Symptomatic Bone metastases from Multiple Myeloma

Because multiple myeloma patients have multiple bone lesions and live for an extended period of time with bone lesions, many patients have more than one course of palliative RT for bone pain. Shorter courses of therapy are not only more convenient for patients and their families, but they also have less impact on timing of systemic therapies. The primary objective of this study is to determine whether treatment with 2Gy x 2 to a painful myeloma bone lesion achieves patient-reported pain reduction comparable to historical controls at 4 weeks.

Principal Investigators
Dr Leslie Ballas (University of Southern California; now at Cedars-Sinai)
Participating Institutions
University of Southern California, Dana-Farber/Brigham and Women's, Mount Sinai, University of Pennsylvania, Emory, Massachusetts General Hospital

Results were presented at the 2026 ASTRO Annual Meeting: 63 evaluable patients at seven institutions, and 81% achieved pain control without additional radiation.

Download the protocol (PDF)NCT03858205 on ClinicalTrials.govASTRO 2026 news release

Collaborative Studies

Published 2025

Relapsed/refractory B-cell lymphoma

Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study

172 patients from 10 institutions received bridging radiotherapy before CAR T-cell therapy between 2018 and 2020. Grade 3 or higher radiotherapy toxicity occurred in 2%. Two-year progression-free and overall survival were 38% and 53%. On multivariable analysis, comprehensive bridging radiotherapy (treating all sites of disease) was associated with longer progression-free survival (HR 0.38) and overall survival (HR 0.48).

Principal Investigators
Dr Nikhil Yegya-Raman and Dr John Plastaras (University of Pennsylvania)

Blood Advances, 2025

Published 2026

Indolent primary cutaneous B-cell lymphoma

Radiotherapy for Indolent Primary Cutaneous B-Cell Lymphoma: An International Multicenter ILROG Analysis

535 patients from 22 centers with limited cutaneous marginal zone or follicle center lymphoma. Response rates did not differ significantly between doses of 4 Gy or less and higher doses, but 5-year local control was lower with 4 Gy or less (73% vs 96%). Low-dose treatment had a favorable toxicity profile, and dose did not affect overall survival.

Principal Investigators
Dr Michael Oertel and Prof Hans Theodor Eich (University Hospital of Münster)

Blood, 2026

Published 2025

Bilateral indolent orbital adnexal lymphoma

An International Lymphoma Radiation Oncology Group Study of Radiation Therapy for Bilateral Indolent Orbital Adnexal Lymphomas

184 patients from 16 centers with synchronous or metachronous bilateral disease were treated with radiotherapy to both orbits; 92% had marginal zone lymphoma. Long-term outcomes support treating bilateral orbital adnexal lymphoma as a localized process with curative-intent radiotherapy.

Principal Investigators
Dr Andrew Wirth (Peter MacCallum Cancer Centre)

IJROBP, 2025

Published 2025

Relapsed/refractory large B-cell lymphoma

Impact of Myc-Altered Pathology on Radiation Therapy Efficacy Among Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Collaborative Study by ILROG

211 patients with known double- or triple-hit status received radiotherapy for relapsed or refractory disease. Double-hit pathology did not change the rate of response to radiotherapy, but it was associated with more local recurrences, which suggests these tumors may be more radioresistant.

Principal Investigators
Dr Yolanda Tseng (University of Washington) and Dr John Plastaras (University of Pennsylvania)

IJROBP, 2025